In Review: Senate Bill 1366 was introduced and scheduled for a hearing in the Insurance and Real Estate Committee on Thursday, February 27^,at 10:00 A.M. The bill includes “delinking”, a fiduciary duty to the health plan, patients, and pharmacies, and a ban on spread pricing. PCMA will meet with House leadership in Hartford again next week to discuss the issues and costs associated with the bill. PCMA has pivoted the “Lower the List Price” ad campaign to a “delinking” campaign. The Office of Health Strategy released two reports this week. The first is the PBM practices report, which includes increasing biosimilar adoption, assessing the potential impact of point-of-sale rebates, lowering patient cost share for brand-over-generic strategies, promoting cost-plus pricing models, and reducing cross-subsidization, “delinking” PBM revenue and drug cost, and expanding the use of preventive drug lists. PCMA submitted a comment letter to the Chairs of the Rx Drug Task Force. The comment letter addressed the issues with the proposed policies along with fiscal analyses done by PCMA. The Rx Drug Task Force Final meeting has been postponed to a later date.

If you have any questions, please contact Sam Hallemeier at shallemeier@pcmanet.org.